NowoTrade

BGM

BGM BGM Group Ltd.

Stock · NasdaqCM · China · Healthcare · KYG7307E1310

NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by BGM Group Ltd., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price 8.25 USD -8.33%
52-week range 6.45 – 291.30
Dividend yield—
Market cap110.2M
NowoTrade score 34 Grade B

Price history

Daily prices in USD.

Updated 08 Nov 2026 14:53. Information, not advice.

Results

Next results —No date announced yet
Last results —Nothing reported yet
Beat the estimate — 
Average surprise — reported against the estimate, last 0 quarters

Quarterly results

DateEPS estimateEPS reportedSurpriseResult
16 Mar 2026 16:00 — — — —

Annual results · USD

YearRevenueChangeNet income Net marginEPSEPS changeFree cash flow
2025 37.9M +51.1% -19.9M -52.6% -0.18 +10.0% -4.6M
2024 25.1M -46.0% -1.4M -5.7% -0.20 +81.5% -3.4M
2023 46.5M -28.3% -7.8M -16.7% -1.08 -820.0% -3.4M
2022 64.9M — 1.1M 1.7% 0.15 — 9.4M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Price history in USD, by week
PeriodOpening priceHighLow Closing priceChangeVolumeDividend
02 Nov 2026 – 06 Nov 2026 In progress 9.54 9.56 7.95 8.25 -13.52% 30,400
26 Oct 2026 – 30 Oct 2026 7.75 9.87 7.75 9.54 +21.53% 22,800
19 Oct 2026 – 23 Oct 2026 9.35 10.66 7.70 7.85 -9.25% 101,400
12 Oct 2026 – 16 Oct 2026 10.74 10.74 8.59 8.65 -19.53% 31,300
05 Oct 2026 – 09 Oct 2026 9.28 10.78 8.36 10.75 +15.10% 18,900
28 Sep 2026 – 02 Oct 2026 7.20 10.80 6.45 9.34 +29.72% 87,596
21 Sep 2026 – 25 Sep 2026 7.47 8.34 6.90 7.20 -4.38% 12,231
14 Sep 2026 – 18 Sep 2026 7.80 8.70 7.02 7.53 -4.56% 6,902
08 Sep 2026 – 11 Sep 2026 8.73 9.90 7.89 7.89 -7.72% 12,107
31 Aug 2026 – 04 Sep 2026 9.54 9.60 7.80 8.55 -13.11% 12,650
24 Aug 2026 – 28 Aug 2026 8.01 9.90 6.87 9.84 +25.19% 41,607
17 Aug 2026 – 21 Aug 2026 8.07 11.55 7.56 7.86 -9.97% 152,616
10 Aug 2026 – 14 Aug 2026 9.00 9.57 8.40 8.73 -3.00% 8,116
03 Aug 2026 – 07 Aug 2026 8.55 9.30 8.34 9.00 +6.38% 7,234
27 Jul 2026 – 31 Jul 2026 9.15 9.15 7.92 8.46 -2.76% 4,633
20 Jul 2026 – 24 Jul 2026 8.88 9.45 7.50 8.70 +2.84% 9,304
13 Jul 2026 – 17 Jul 2026 10.17 10.35 8.31 8.46 -15.82% 17,243
06 Jul 2026 – 10 Jul 2026 9.72 14.40 9.12 10.05 +3.40% 237,680
29 Jun 2026 – 02 Jul 2026 9.69 11.70 9.69 9.72 +0.31% 7,710
22 Jun 2026 – 26 Jun 2026 10.80 11.13 9.45 9.69 -11.51% 9,054
15 Jun 2026 – 18 Jun 2026 11.40 15.00 10.50 10.95 -2.67% 65,567
08 Jun 2026 – 12 Jun 2026 8.73 13.50 8.73 11.25 +28.87% 265,984
01 Jun 2026 – 05 Jun 2026 9.42 11.85 8.49 8.73 -8.20% 58,537
26 May 2026 – 29 May 2026 8.49 10.11 8.49 9.51 +8.56% 16,833
18 May 2026 – 22 May 2026 9.48 9.90 7.68 8.76 -15.12% 43,759
Page 1 of 11

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

Key data

Previous close
9.00 USD
Market cap
110.2M
Last dividend
7.5000 USD · 27 Feb 2023
Exchange
NasdaqCM
Country
China
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD

Dividends

Ex-dividend datePer share
27 Feb 20237.5000 USD

Why this score

How the score is made up
Part of the scorePointsWhy
Business growth Yearly growth of revenue and of earnings per share. 0.0 / 25
  • Revenue growth of -16.4% a year
Quality Return on equity, net margin and how stable the margins are. 0.0 / 25
  • ROE of -7%
Financial strength Net debt against operating earnings, interest cover and free cash flow. 20.0 / 20
  • Free cash flow yield of 10.2%
Valuation Free cash flow yield and the P/E against its sector. 14.8 / 15
  • Price / sales 2.3: it has no profit to price yet
Analysts How far the analysts' average target is from today's price. 3.5 / 10 No figures for this part: it counts as a cautious 35%. —
  • Score capped at 60: free cash flow was negative in two of the last three years
  • The last full year was a loss

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 85% of the figures (grade B). Warnings take 6 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.

Figures

Valuation
FigureValueReading Sector median
Price / book 0.14× Good 3.81×
Price / sales 2.3× Fair 3.19×
EV / EBITDA -5.01× Weak 12.63×
Free cash flow yield 10.2% Good 2.5%
Quality
FigureValueReading Sector median
Gross margin 16.9% Weak 58.6%
Operating margin -3.6% Weak 7.8%
Net margin -44.2% Weak 2.8%
Return on equity -7.4% Weak 5.7%
Return on assets -2.2% Weak 3.6%
Growth
FigureValueReading Sector median
Revenue growth / year -16.4% Weak 10.8%
Financial health
FigureValueReading Sector median
Debt / equity 0× Good 0.48×
Current ratio 1.25× Fair 2.39×
Dividends
FigureValueReading Sector median
Payout of earnings 0% Weak 0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Follow BGM and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in